Kashif Memon, MD
Internal Medicine · Vernal, UTNPI 1932161668
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,173 of the $72,578 with a category attached, or 87.0%. AbbVie accounts for 80.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $19,145 and has fallen 67.2% since, to $6,285 in 2025. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $403.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$59K
- Mylan Specialty L.p.$6K
- La Jolla Pharmaceutical Company$2K
- Ferring Pharmaceuticals Inc.$2K
- BD$900
- Vertex$500
- plus $2K from 19 others
What the payments were for
- Consulting fees$2,2203%
- Speaking & faculty fees$63,17387%
- Travel & lodging$3,9075%
- Food & beverage$2,6864%
- Education$5931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 119 | $58,719 |
| Mylan Specialty L.p. | 12 | $6,354 |
| La Jolla Pharmaceutical Company | 3 | $2,266 |
| Ferring Pharmaceuticals Inc. | 4 | $1,725 |
| BD | 2 | $900 |
| Vertex | 1 | $500 |
| Melinta Therapeutics, LLC | 5 | $409 |
| Biofire Diagnostics, LLC | 1 | $325 |
| Viiv Healthcare Company | 10 | $300 |
| Cepheid | 1 | $300 |
| ZOLL Medical Corporation | 1 | $203 |
| GSK | 1 | $120 |
| Comsort, Inc | 1 | $100 |
| Insmed, Inc. | 4 | $81 |
| Inspire Medical Systems, Inc. | 2 | $47 |
| Paratek Pharmaceuticals, Inc. | 2 | $37 |
| Biomerieux Inc | 1 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Amgen | 1 | $25 |
| Merck | 2 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,578 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 13 | $198,241 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 22 | $84,821 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 11 | $53,221 |
| ErtapenemErtapenem Sodium | 53 | $17,645 |
| Daptomycin | 42 | $13,238 |
| Cefdinir | 169 | $10,706 |
| Meropenem | 66 | $7,478 |
| Sodium Chloride0.9 % Sodium Chloride | 172 | $4,824 |
| Doxycycline Hyclate | 157 | $4,298 |
| Linezolid | 16 | $3,413 |
| CefuroximeCefuroxime Axetil | 39 | $3,071 |
| Methenamine Hippurate | 49 | $2,914 |
| MicafunginMicafungin Sodium | 12 | $2,545 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 19 | $1,993 |
| Rifampin | 35 | $1,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $81 | $198,24113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Vernal
- Willard DereSalt Lake City$4.7M
- Kenneth SchaecherWest Valley City$333K
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Barbara RizzardiSandy$30K
- Gerald GleichSalt Lake City$22K
- Brian HornerSalt Lake City$21K
- Jahangir ImaniWashington Terrace$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.